that change-up of verbiage on the CC made it seem like they would have already had
a $ deal on the table

maybe they sill do, as these types of contracts take a long time to consummate

hopefully the last revised Series E (even though slated towards ESS) is a $ bridge to an eventual LymPro financial deal

also those statements regarding Neuraceq are customary and cautionary, as Neuraceq was approval by the FDA

http://www.prnewswire.com/news-releases/fda-a...16031.html

Quote:

---

"The FDA approval of Neuraceq™ is based on safety data from 872 patients who participated in global clinical trials as well as three studies that examined images from adults with a range of cognitive function, including 205 end-of-life patients who had agreed to participate in a post-mortem brain donation program. Images were analyzed from 82 subjects with post-mortem confirmation of the presence or absence of beta-amyloid neuritic plaques. Correlation of the visual PET interpretation with histopathology in these 82 brains demonstrated that Neuraceq™ accurately detects moderate to frequent beta-amyloid neuritic plaques in the brain and is a useful tool to estimate the density of these plaques in life."

---

however, $3-Bil. is just a hair more that AMBS has for acquisition - my bad